Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and 18F-FDG-PET

• Published in: Breast cancer (Tokyo, Japan) Vol. 25; no. 3; pp. 334 - 342
• Main Authors: Nguyen-Thu, Huong, Hanaoka, Hirofumi, Nakajima, Takahito, Yamaguchi, Aiko, Nguyen-Cong, Tien, Kartamihardja, A. Adhipatria P., Tsushima, Yoshito
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.05.2018
• Subjects: Cancer Research; Medicine; Medicine & Public Health; Oncology; Original Article; Surgery; Surgical Oncology; Early response prediction; F-FDG-PET; Diffusion-weighted MRI; Triple negative breast cancer; Cisplatin
• DOI: 10.1007/s12282-018-0834-z
• ISSN: 1340-6868

Background We evaluated the potential of diffusion-weighted MRI (DW-MRI) and 18 F-FDG-PET for the early prediction of a triple negative breast cancer (TNBC) response to cisplatin. Methods Cisplatin-treated TNBC tumor-bearing mice were categorized as responders or non-responders based on the tumor growth rate. DW-MRI and 18 F-FDG-PET were performed before and after treatment (day 0 and days 3 and 7, respectively). The average apparent diffusion coefficient value (ADC mean ), the highest standardized uptake value (SUV max ), and the metabolic tumor volume (MTV) were measured. The ratios of each parameter relative to day 0 were calculated [ΔADC mean (day 3) and (day 7), ΔSUV max (day 3) and (day 7), and ΔMTV (day 3) and (day 7), respectively]. Overall survival rates were compared based on the thresholds determined by these parameters. Results Both the day 3 and day 7 ratios of ADC mean and MTV showed significant differences between the responder and non-responder groups, whereas the ratios of SUV max did not. Mice with ΔADC mean (day 3) exceeding the threshold showed a longer overall survival rate. Mice with ΔSUV max (day 7), ΔMTV (day 3), and ΔMTV (day 7) below the respective thresholds showed a longer overall survival rate. Conclusions The ratios of ADC mean , SUV max , and MTV have the potential to predict the therapeutic response and to screen non-responders in the ultra-early phase following cisplatin treatment in patients with TNBC.